首頁 > 市場調查報告書 > 製藥

癌症

Gemcitabine鹽酸鹽市場規模、佔有率及成長分析（按類型、應用、通路和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1914024

Gemcitabine鹽酸鹽市場規模、佔有率及成長分析（按類型、應用、通路和地區分類）－2026-2033年產業預測

Gemcitabine Hydrochloride Market Size, Share, and Growth Analysis, By Type (Branded, Generic), By Application (Pancreatic Cancer, Non-Small Cell Lung Cancer), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月30日 | 出版商:

SkyQuest | 英文 198 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球吉西他濱Gemcitabine市場規模將達到 23.3 億美元，到 2025 年將達到 24.6 億美元，到 2033 年將達到 38.3 億美元，預測期（2026-2033 年）的複合年成長率為 5.7%。

受胰腺癌、卵巢、肺癌和乳癌等多種癌症發病率上升的推動，全球Gemcitabine鹽酸鹽市場正經歷顯著成長。作為一種領先的化療藥物，Gemcitabine是多種固態腫瘤治療方法的基石。癌症發生率的快速上升，主要歸因於人口老化、生活方式因素和日益嚴重的環境風險，這導致新興經濟體醫療保健服務可近性和化療使用率的提高。此外，藥物製劑的創新，例如脂質體遞送系統和聯合治療，正在提高醫生對Gemcitabine治療的接受度和患者適用性。專利到期帶來的學名藥湧入進一步改善了藥物可近性，而不斷上漲的醫療成本和對個人化癌症治療日益成長的關注，都預示著已開發國家和開發中國家的吉西他濱市場將持續擴張。

全球吉西他濱鹽酸Gemcitabine市場促進因素

全球癌症發生率的不斷攀升，尤其是胰臟癌、肺癌、乳癌和膀胱癌等癌症，正顯著推動Gemcitabine市場的發展。由於其療效顯著且毒性可控，Gemcitabine已成為多種癌症治療的基石治療方法。此外，目前正在進行的研究和臨床試驗，探索Gemcitabine的新適應症和聯合治療，有望維持並進一步提升其市場需求。人們對Gemcitabine在綜合癌症治療方法中的效用認知不斷提高，這不僅增強了其在腫瘤治療領域的地位，也鞏固了其作為對抗常見癌症的關鍵藥物的市場地位。

限制全球吉西他濱鹽酸Gemcitabine市場的因素

隨著品牌Gemcitabine製劑專利到期，大量學名藥湧現，導致市場價格競爭異常激烈。雖然選擇增多有利於消費者獲得藥物，但也給Gemcitabine價格帶來了顯著的下行壓力，從而擠壓了現有生產商的利潤空間。這種情況可能抑制研發投入，阻礙創新以及新適應症和先進給藥方案的開發。因此，全球鹽酸Gemcitabine市場面臨著限制其整體成長並限制新治療方案發展的許多因素。

全球吉西他濱鹽酸Gemcitabine市場趨勢

全球吉西他濱Gemcitabine市場正經歷著一個關鍵趨勢，即人工智慧 (AI) 在個人化化療中的應用。主要企業正利用人工智慧和數據分析來最佳化治療方案、實現即時病患監測並促進預測建模。這項創新使得個人化給藥方案的開發成為可能，從而最大限度地提高療效並最大限度地減少副作用。隨著醫療機構擴大採用這些先進技術，癌症治療的整體水平有望得到提升，這標誌著腫瘤治療正朝著更加精準和以患者為中心的方向發展。這一趨勢有望推動市場成長，並吸引更多投資用於創新治療方案。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Eli Lilly and Company（USA）
Teva Pharmaceutical Industries Ltd.（Israel）
Pfizer Inc.（USA）
Mylan NV（USA）
Fresenius Kabi AG（Germany）
Accord Healthcare（United Kingdom）
Sun Pharmaceutical Industries Ltd.（India）
Dr. Reddy's Laboratories（India）
Cipla Ltd.（India）
Aurobindo Pharma（India）
Sandoz International GmbH（Germany）

結論與建議

簡介目錄

Product Code: SQMIG35I2437

Global Gemcitabine Hydrochloride Market size was valued at USD 2.33 Billion in 2024 and is poised to grow from USD 2.46 Billion in 2025 to USD 3.83 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

The global market for Gemcitabine Hydrochloride is witnessing notable growth driven by the increasing incidence of various cancers, including pancreatic, ovarian, lung, and breast types. As a key chemotherapy agent, Gemcitabine serves as a fundamental treatment for numerous solid tumors. The surge in cancer rates is largely attributed to aging populations, lifestyle factors, and heightened environmental risks, resulting in greater healthcare access and chemotherapy use in emerging economies. Additionally, innovations in drug formulation, such as liposomal delivery systems and combination therapies, are enhancing physician adoption and patient eligibility for Gemcitabine regimens. The influx of generic alternatives following patent expirations has further improved access, while rising healthcare expenditures and an emphasis on personalized oncology therapies signal ongoing market expansion across both developed and developing regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gemcitabine Hydrochloride market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gemcitabine Hydrochloride Market Segments Analysis

Global Gemcitabine Hydrochloride Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generic. Based on Application, the market is segmented into Pancreatic Cancer, Non-Small Cell Lung Cancer, Breast Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gemcitabine Hydrochloride Market

The growing prevalence of cancer worldwide, particularly types such as pancreatic, lung, breast, and bladder cancers, significantly propels the gemcitabine hydrochloride market. Its effectiveness and manageable toxicity have established gemcitabine hydrochloride as a fundamental treatment in various cancer therapies. Furthermore, ongoing research and clinical trials investigating new indications and combination therapies that include gemcitabine are likely to sustain and boost its demand. This expanding recognition of gemcitabine's utility in comprehensive cancer treatment regimens enhances its role in oncology, solidifying its market position as a vital component in combating these prevalent cancers.

Restraints in the Global Gemcitabine Hydrochloride Market

The emergence of numerous generic alternatives following the expiration of patents on branded gemcitabine formulations has triggered fierce price competition within the market. While the availability of more options enhances accessibility for consumers, it also exerts significant downward pressure on gemcitabine pricing, consequently squeezing profit margins for established manufacturers. This scenario can deter investment in research and development, stifling innovation and the potential for introducing new indications or advanced delivery methods. As a result, the global gemcitabine hydrochloride market faces constraints that hinder its overall expansion and limit the advancement of new therapeutic options.

Market Trends of the Global Gemcitabine Hydrochloride Market

The Global Gemcitabine Hydrochloride market is witnessing a significant trend driven by the integration of Artificial Intelligence in personalized chemotherapy. Major players are leveraging AI and data analytics to enhance treatment planning, facilitating real-time patient monitoring and predictive modeling. This innovation enables the development of individualized dosing regimens, tailored to maximize therapeutic efficacy while minimizing adverse effects. As healthcare providers increasingly adopt these advanced technologies, the overall delivery of cancer treatment is expected to improve, marking a shift towards more precise and patient-centric approaches in oncology. This trend is likely to spur market growth and attract further investment in innovative treatment solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Gemcitabine Hydrochloride Market Size by Type & CAGR (2026-2033)

Market Overview
Branded
Generic Gemcitabine Hydrochloride

Global Gemcitabine Hydrochloride Market Size by Application & CAGR (2026-2033)

Market Overview
Pancreatic Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Others

Global Gemcitabine Hydrochloride Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Gemcitabine Hydrochloride Market Size & CAGR (2026-2033)

North America (Type, Application, Distribution Channel)
- US
- Canada
Europe (Type, Application, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Application, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Application, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Application, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Accord Healthcare (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments